Breaking Finance News

Zacks Investment Research downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) to Hold in a report released today.

Yesterday Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded 2.69% higher at $3.91. The company’s 50-day moving average is $3.77 and its 200-day moving average is $4.09. The last closing price is down -1.94% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 1,582,598 shares of the stock traded hands, down from an average trading volume of 2,386,640

Zacks Investment Research has downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) to Hold in a report released on 11/29/2016.

Previously on 11/28/2016, Zacks Investment Research reported on Celldex Therapeutics, Inc. (NASDAQ:CLDX) increased the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 0.13%.

See Chart Below

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Celldex Therapeutics, Inc. has a 52 week low of $2.85 and a 52 week high of $18.31 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 11 brokers have issued a report on the company. The average stock price target is $31.27 with 6 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response against their cancer. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *